Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > A step forward in prostate cancer screening optimisation
  • News

A step forward in prostate cancer screening optimisation

  • 26 February 2020
  • Elena Riboldi
Total
0
Shares
0
0
0
0
0
A single prostate-specific antigen (PSA) measurement in midlife may help to personalise prostate cancer screening, resulting in a reduced risk of overdiagnosis and overtreatment of indolent cancers. The authors of the study just published in JAMA Network Open came to this conclusion after finding that in a cohort of nearly 11,000 man aged 55 to 60 years, baseline PSA level correlated with long-term risk of clinically significant prostate cancer. This study is likely to re-open the debate about the utility of PSA measurement as a screening tool. Introduced in the 1990s, it enjoyed wide acceptance until recent years, when its significance has been called into question. “Until a more accurate biomarker is identified, PSA remains the best screening tool available for early prostate cancer diagnosis” stated Evan Kovac, urologist at Montefiore Medical Center (Bronx, New York) and first author of the article. “Therefore, it is imperative to improve the detection of clinically significant prostate cancer while minimizing overdiagnosis and overtreatment through a more nuanced approach to PSA screening.” The study consisted in a secondary analysis of a cohort of 10,968 men aged 55 to 60 years enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The risk of being diagnosed with a clinically significant prostate cancer during 13 years of follow-up was lower among men with a baseline PSA level less than 0.49 ng/mL and higher among men with a baseline level more than 2.00 ng/mL. Of note, 83% of participants had baseline PSA levels less than 2.00 ng/mL. “At a time when the concern regarding the overdiagnosis and overtreatment of indolent prostate cancer has led to intense scrutiny of the value of PSA levels as an effective screening tool, our data on the increasing risks associated with higher baseline PSA levels can be used to determine the optimal prostate cancer screening strategy for individual patients – Kovac explained – The low 13-year actuarial risk of a clinically significant prostate cancer diagnosis in middle-aged men with a baseline PSA level less than 2.00 ng/mL suggests that men younger than 60 years with PSA levels of 1.00 to 1.99 ng/mL can undergo less intensive screening than men with higher baseline PSA levels. Men with baseline PSA levels less than 1.00 ng/mL may wish to discontinue screening.” Data from this study may be used to inform patients for shared decision-making.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • PSA
  • screening
Avatar
Elena Riboldi

Previous Article
  • Profiles

Chiara Gasparotto – winning the case for better access to radiotherapy

  • 11 February 2020
  • yAntonio
View Post
Next Article
  • News

More evidence-based info on off-patent oncology drugs

  • 2 March 2020
  • Editorial Staff
View Post
You May Also Like
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Integrated imaging opens the way for virtual biopsies

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Cancer survivors at greater risk of subsequent primary cancers

  • Janet Fricker
  • 30 December 2020
View Post
  • News

Immunotherapy cardiotoxicity higher than previously estimated

  • Janet Fricker
  • 24 December 2020
NHS cancer screening blood test
View Post
  • News

NHS England’s pilot of cancer screening blood test raises questions

  • Janet Fricker
  • 21 December 2020
View Post
  • News

Building back cancer services after Covid-19: European Cancer Organisation plan

  • Janet Fricker
  • 2 December 2020
View Post
  • News

Prolonged ADT use in prostate cancer increases CV mortality: A need for cardiovascular protection

  • Janet Fricker
  • 27 November 2020

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • Coffee may protect against prostate cancer
    • 20 January 2021
  • Financial burden on older adults with advanced cancer worsens quality of life
    • 15 January 2021
  • Integrated imaging opens the way for virtual biopsies
    • 15 January 2021
  • Cancer survivors at greater risk of subsequent primary cancers
    • 30 December 2020
  • Immunotherapy cardiotoxicity higher than previously estimated
    • 24 December 2020
Latest printed issue
Article
  • Berlin pilot project brings precision care to the peripheries
    • 15 January 2021
  • Highlights of 2020 American Society of Hematology (ASH) meeting
    • 14 January 2021
  • Highlights of 2020 San Antonio Breast Cancer Symposium
    • 28 December 2020
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Prof Gordon McVie 1945 – 2021
    • 22 January 2021
  • From the New Yorker: What Cancer Takes Away
    • 22 January 2021
  • Interview to Christian Rolfo
    Liquid biopsy for early stage lung cancer moves closer
    • 12 January 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy
Archivio Cancerworld

Input your search keywords and press Enter.